The US Food and Drug Administration review last year regarding Sage Therapeutics, Inc./Biogen, Inc.’s Zurzuvae (zuranolone) was not a sure bet and resulted in a split decision – approval for postpartum depression (PPD), but not for major depressive disorder (MDD). This year, Sage is focused on Zurzuvae’s PPD launch, while also preparing to turn over the cards on two new bets, both outside of the depression market.
Sage Ready To Turn Over Cards On Bets Outside Of Depression
Five Clinical Trial Readouts Expected In 2024
Sage has two postpartum depression drugs on the market, but will read out mid-stage trials this year for two candidates in Huntington’s, Parkinson’s and Alzheimer’s diseases and essential tremor.
